Low-dose statins: useful and safe?

Abstract

This article considers the raison d'être for the use of low-dose statins, their safety, efficacy and potential as non-prescription drugs. It is very much a personal contribution to a controversial area which has become very topical.

Keywords

statins low-dose primary prevention dyslipidaemia combination therapy.

Get full access to this article

View all access options for this article.

References

Leader. Don't restrict heart drugs to those who can pay for them. The Independent 13 May 2004.

Editorial. OTC statins: a bad decision for public health. Lancet 2004 ; 363:1659.

Law MR , Wald NJ , Rudnicka AR Quantifying effects of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423.

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.

Saku K. , Sasaki J. , Arakawa K. Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolaemia. Clin Ther 1989;11:247-57.

Lepre F. , Nestel I. , Clifton P. , Lloyd B. , Morgan T. Low-dose simvastatin in the treatment of mild to moderate hypercholesterolaemia . Clin Drug Invest 1997;13:237-41.

Mabuchi H. , Kita T. , Matsuzaki M. et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-doses simvastatin therapy in Japanese patients with hypercholesterolaemia and coronary heart disease. Circ J 2002;66:1096-100.

Farmer JA Learning from the cerivastatin experience. Lancet 2001;358: 1383-5.

Thompson PD , Clarkson P. , Karas RH Statin-associated myopathy. JAMA 2003 ;289:1681-90.

10.

Parra JL , Reddy KR Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis 2003;7:415-33.

11.

Omar MA , Wilson JP FDA adverse event reports on statin-associated rhabdomyolysis. Pharmacother 2002;36:288-95.

12.

Martin J. , Krum H.

Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant?

Drug Saf 2003 ; 26:13-21.

13.

Stein EA , Davidson MH , Dujovne CA et al. Efficacy and safety of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: a prospective trial. J Cardiovasc Pharmacol Ther 1996;1:107-16.

14.

Vega GL , Ma PTS , Cater NB et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 2003;91:956-60.

15.

Nutescu EA , Shapiro NL Ezetimibe: a selective cholesterol absorption inhibitor. Pharmacotherapy 2003;23:1463-74.

16.

Davidson MH , McGarry T. , Bettis R. et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolaemia. J Am Coll Cardiol 2002;40:2125-34.

17.

Cannon CP , Braunwald E. , McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004 ;350:1495-504.

18.

Williams B. , Poulter NR , Brown MJ et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328:634-40.

19.

Shepherd J. Statins for primary prevention: strategic options to save lives and money. J R Soc Med 2004;97:66-71.